NCT01725217

Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia

A Phase 3, Multi-center, Open-label Study to Evaluate Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine (MenACWY-CRM) in Healthy Children, Adolescents and Adults in Russia

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 198 (actual)
• Sponsor: Novartis Vaccines · Industry
• Sex: All
• Age: 2 Years
• Healthy volunteers: Accepted

Summary

To evaluate the immune response and safety following a single dose of Novartis Meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy children, adolescents and adults in Russia.

Conditions

• Meningococcal Disease

Interventions

Type	Name	Description
BIOLOGICAL	MenACWY-CRM	1 vaccination at visit 1, conjugate vaccine, Intramuscular (IM) injection

Timeline

• Start date: 2012-11-01
• Primary completion: 2013-03-01
• Completion: 2013-03-01
• First posted: 2012-11-12
• Last updated: 2023-04-28
• Results posted: 2014-03-18

Locations

4 sites across 1 country: Russia